These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 7906521)

  • 1. Metabolism of phenothiazine and butyrophenone antipsychotic drugs. A review of some recent research findings and clinical implications.
    Hubbard JW; Midha KK; Hawes EM; McKay G; Marder SR; Aravagiri M; Korchinski ED
    Br J Psychiatry Suppl; 1993 Dec; (22):19-24. PubMed ID: 7906521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic activation of the phenothiazine antipsychotics chlorpromazine and thioridazine to electrophilic iminoquinone species in human liver microsomes and recombinant P450s.
    Wen B; Zhou M
    Chem Biol Interact; 2009 Oct; 181(2):220-6. PubMed ID: 19482014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of antipsychotic drugs on body weight: a retrospective review.
    Doss FW
    J Clin Psychiatry; 1979 Dec; 40(12):528-30. PubMed ID: 40965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates.
    El Ela AA; Härtter S; Schmitt U; Hiemke C; Spahn-Langguth H; Langguth P
    J Pharm Pharmacol; 2004 Aug; 56(8):967-75. PubMed ID: 15285840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
    Baptista T; Kin NM; Beaulieu S; de Baptista EA
    Pharmacopsychiatry; 2002 Nov; 35(6):205-19. PubMed ID: 12518268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.
    Herrick-Davis K; Grinde E; Teitler M
    J Pharmacol Exp Ther; 2000 Oct; 295(1):226-32. PubMed ID: 10991983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents.
    Murray M
    J Pharm Pharmacol; 2006 Jul; 58(7):871-85. PubMed ID: 16805946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chlorpromazine equivalents versus defined daily doses: how to compare antipsychotic drug doses?
    Rijcken CA; Monster TB; Brouwers JR; de Jong-van den Berg LT
    J Clin Psychopharmacol; 2003 Dec; 23(6):657-9. PubMed ID: 14624195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans.
    Hartigan-Go K; Bateman DN; Nyberg G; Mårtensson E; Thomas SH
    Clin Pharmacol Ther; 1996 Nov; 60(5):543-53. PubMed ID: 8941027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation.
    Jann MW; Fidone GS; Hernandez JM; Amrung S; Davis CM
    Psychiatry Res; 1989 May; 28(2):153-9. PubMed ID: 2568651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postmortem redistribution of two antipsychotic drugs, haloperidol and thioridazine, in the rat.
    Castaing N; Titier K; Canal-Raffin M; Moore N; Molimard M
    J Anal Toxicol; 2006 Sep; 30(7):419-25. PubMed ID: 16959133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of phenothiazine neuroleptics after chronic coadministration of carbamazepine.
    Daniel WA; Syrek M; Haduch A; Wójcikowski J
    Pol J Pharmacol; 1998; 50(6):431-42. PubMed ID: 10385926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery.
    Samaha AN; Reckless GE; Seeman P; Diwan M; Nobrega JN; Kapur S
    Biol Psychiatry; 2008 Jul; 64(2):145-52. PubMed ID: 18295747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of human cytochrome p450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine.
    Wójcikowski J; Maurel P; Daniel WA
    Drug Metab Dispos; 2006 Mar; 34(3):471-6. PubMed ID: 16272405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs.
    Andreasen NC; Pressler M; Nopoulos P; Miller D; Ho BC
    Biol Psychiatry; 2010 Feb; 67(3):255-62. PubMed ID: 19897178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
    Arranz MJ; de Leon J
    Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic.
    Ereshefsky L
    J Clin Psychiatry; 1999; 60 Suppl 10():20-30. PubMed ID: 10340684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of d-limonene, alpha-pinene and cineole on in vitro transdermal human skin penetration of chlorpromazine and haloperidol.
    Almirall M; Montaña J; Escribano E; Obach R; Berrozpe JD
    Arzneimittelforschung; 1996 Jul; 46(7):676-80. PubMed ID: 8842336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.